2025-03-01 · sleeve gastrectomy, vertical sleeve gastrectomy, VSG, bariatric surgery, weight loss surgery, ghrelin, type 2 diabetes remission, surgical, bariatric

Updated 2026-07-28

How much weight do most people lose after sleeve gastrectomy?

Typical results are roughly 25–30% of total body weight (about 55–70% of excess weight) at 12–18 months post-op. The SLEEVEPASS 10-year extension (Salminen 2022, JAMA Surgery) reported mean 47% excess-weight loss at a decade, and the SM-BOSS trial (Peterli 2018, JAMA) showed similar mid-term durability. Most of the loss happens in the first year; year two often adds a smaller amount, and 5–10 percentage points of regain from the one-year peak by year five is normal. Patients who keep protein at roughly 0.7–1.0 g/lb, stay engaged with follow-up, and add resistance training tend to hold the largest fraction of their loss.

What is the difference between sleeve gastrectomy and gastric bypass?

Sleeve gastrectomy removes about 80% of the stomach and leaves the intestines alone; gastric bypass creates a small stomach pouch and reroutes it to the middle of the small intestine, which is both restrictive and moderately malabsorptive. In head-to-head trials (SLEEVEPASS, SM-BOSS) five- and ten-year weight loss and quality-of-life scores are broadly similar, but bypass produces somewhat higher type 2 diabetes remission and improves rather than worsens reflux. Sleeve is technically simpler, has fewer nutrient-deficiency concerns, and preserves normal digestive anatomy. See [gastric bypass surgery](/weight-loss/gastric-bypass-surgery/) for the full head-to-head.

Is sleeve gastrectomy reversible?

No — the removed portion of the stomach is discarded, so the anatomy cannot be restored. If a sleeve fails to produce adequate weight loss, causes severe GERD or Barrett's esophagus, or the patient regains substantially, the standard next step is a conversion procedure rather than a reversal: sleeve-to-Roux-en-Y gastric bypass is the most common conversion (especially for reflux) and sleeve-to-duodenal-switch is chosen for inadequate weight loss at high BMI. See [bariatric surgery revision](/weight-loss/bariatric-surgery-revision/) for the decision framework, endoscopic alternatives (TORe, re-sleeve), and when a GLP-1 trial is the right first move before returning to the OR.

Will I have reflux after a sleeve?

Reflux is the single most important sleeve-specific drawback to talk through pre-op. Roughly 20–30% of sleeve patients develop new or worsened GERD symptoms, and long-term follow-up shows a measurable rate of Barrett's esophagus at 10 years (SLEEVEPASS 2022). Patients with existing significant reflux, hiatal hernia, or Barrett's are usually steered toward Roux-en-Y gastric bypass — which improves rather than worsens reflux — rather than a sleeve. Post-op reflux is managed initially with PPIs, meal timing, and head-of-bed elevation; if it becomes severe or PPI-refractory, conversion to bypass is the definitive fix.

How long does it take to recover from sleeve gastrectomy?

Most laparoscopic or robotic sleeves are done in about 60–90 minutes, patients stay one night in the hospital, and light activity (walking, showering, driving off narcotics) usually resumes within 3–7 days. Desk-based work returns at 1–2 weeks; jobs with heavy lifting typically need 4–6 weeks. Full return to structured exercise is usually cleared at 6 weeks post-op. The diet progresses in stages — clear liquids, full liquids, pureed, soft, then regular textures — over roughly 6 weeks, with strict portion limits (2–4 ounces) and protein-first ordering for life.

How much does sleeve gastrectomy cost in 2026?

Cash-pay pricing at accredited U.S. centers runs about $15,000–$25,000 for the sleeve itself, with bundled programs typically including surgeon, anesthesia, facility, and initial follow-up. When commercial insurance or Medicare covers the procedure, patients pay their deductible and coinsurance (often $2,000–$6,000 in-network) plus the cost of the pre-op requirements — supervised nutrition visits, psychological evaluation, sometimes a supervised weight-loss period. International medical-tourism prices (Mexico ~$4,500–$8,000) are lower, but the follow-up gap and the harder path to U.S. care for a complication are real trade-offs. See [bariatric surgery cost and insurance coverage](/weight-loss/bariatric-surgery-cost-insurance/) for the full breakdown.

Do you need to take vitamins for life after a sleeve?

Yes. Sleeve gastrectomy is not a malabsorptive operation, but the smaller stomach, reduced acid production, and lower dietary intake meaningfully raise the risk of B12, iron, vitamin D, calcium, thiamine, and folate deficiencies over time. The ASMBS 2022 nutrition guideline recommends a lifelong bariatric-grade multivitamin (typically 200% DV), calcium citrate (1,200–1,500 mg/day in divided doses), vitamin D3 (3,000 IU/day baseline, adjusted to a 25(OH)D target), B12 (350–500 µg/day oral or 1,000 µg IM monthly), and iron for menstruating patients. Annual labs (CBC, iron studies, B12, 25(OH)D, PTH, calcium) catch drift early. See the [bariatric post-op vitamin and nutrition protocol](/weight-loss/bariatric-post-op-vitamin-nutrition-protocol/) for the full stack.

What happens if you regain weight after sleeve gastrectomy?

Some regain is expected — 5–10 percentage points from the one-year peak by year five is average, and about 20–30% of patients experience larger regain. The 2026 stepwise response starts with re-engaging the bariatric team, tightening protein and portion tracking, treating any newly-emerged binge-eating pattern, and — increasingly — trialing a GLP-1 medication (semaglutide or tirzepatide), which produces meaningful additional weight loss in post-sleeve patients without another operation. Endoscopic re-sleeve options exist. Surgical conversion to gastric bypass or duodenal switch is reserved for anatomical failure or when medical and endoscopic options have not worked. Do not wait years to reconnect — early re-engagement is the strongest predictor of recovery.

Sleeve Gastrectomy

Sleeve gastrectomy — often shortened to VSG (vertical sleeve gastrectomy) or simply “the sleeve” — is a bariatric operation that removes about 80% of the stomach along the greater curvature, leaving a narrow, banana-shaped tube. It produces roughly 25–30% total-body-weight loss at one year, works partly by dropping the hunger hormone ghrelin, and is the most commonly performed bariatric procedure in the world. This guide walks through what the sleeve actually is, who qualifies under the current 2022 ASMBS criteria, what the trial data show for weight loss and type 2 diabetes remission, how it compares head-to-head with gastric bypass and GLP-1 medications, what recovery looks like day by day, what it costs, and how to pick a surgeon.

Quick stats

• Procedure duration: typically 60–90 minutes, laparoscopic or robotic.
• Hospital stay: usually one night; some enhanced-recovery programs discharge same day.
• Average excess-weight loss (EWL): ~60% at 1 year, ~55% at 3 years, ~47% at 10 years (Salminen 2022, SLEEVEPASS 10-yr).
• Average total-body-weight loss (TWL): ~25–30% at 1 year, ~20% at 5 years.
• 30-day mortality: approximately 0.1% at accredited U.S. MBSAQIP centers — comparable to gallbladder surgery.
• Revision rate: 10–20% by 10 years, most commonly for GERD or inadequate weight loss.
• Type 2 diabetes remission: 40–60% at 1 year (Schauer 2017, STAMPEDE 5-yr).
• Cost: roughly $15,000–$25,000 cash-pay in the U.S.; deductible + coinsurance when insurance covers.

Who this is for / not for

Good fit if:

• You meet the current surgical criteria (BMI ≥ 35, or ≥ 30 with a metabolic comorbidity under the 2022 ASMBS update) and want durable weight loss without intestinal rerouting.
• You want a shorter operative time and simpler anatomy than gastric bypass.
• You can commit to lifelong protein-forward eating, daily bariatric supplementation, and annual labs.

Not a fit if:

• You have significant reflux, hiatal hernia, or Barrett’s esophagus — the sleeve can worsen GERD, and gastric bypass is usually the better choice.
• You cannot commit to daily supplementation and long-term follow-up.
• You have medical or anesthesia contraindications, active untreated substance-use disorder, or an untreated severe eating disorder.
• You’re looking for a reversible procedure — the removed stomach cannot be restored.

What it is (plain-language definition)

In a sleeve gastrectomy the surgeon removes the outer, curved portion of the stomach along the greater curvature — about 80% of the total organ, including the fundus (dome). What remains is a narrow tube running from the esophagus to the pylorus, roughly the shape and volume of a banana. The pyloric valve at the bottom is preserved, so food still empties into the duodenum in the normal sequence and digestion downstream is unchanged.

Two mechanisms drive the weight loss. The first is straightforward restriction: the smaller stomach holds much less food per meal (typically 2–4 ounces for the first year). The second is hormonal — the fundus is the main site of ghrelin production, the hormone that signals hunger, and its removal produces a large and durable drop in circulating ghrelin. That combination — restriction with a strong appetite-hormone effect — is why the sleeve is often classified as “restrictive with hormonal effect” rather than a purely restrictive operation like the older adjustable gastric band.

Nothing is rerouted. No small-intestine anatomy is bypassed. That preserves normal absorption of most macronutrients but does not eliminate the risk of micronutrient deficiencies over time (see the vitamin section below).

How the sleeve compares to bypass, duodenal switch, and GLP-1

The table below shows the four most-common options a patient with a BMI ≥ 35 or ≥ 30 with metabolic disease is likely to be weighing in 2026. Weight-loss figures are expressed as total-body-weight loss (TWL) at one year for direct comparability.

Two practical patterns fall out of the table. First, the higher-intensity operations produce more weight loss and higher T2D remission but with a bigger lifelong nutrition burden. Second, “reversibility” varies — the sleeve removes anatomy that does not come back, while a GLP-1 stops working when it is stopped. For the full side-by-side of the two most common bariatric operations, see gastric bypass surgery; for drugs versus surgery, including cost, insurance, and decision timing, see bariatric surgery vs GLP-1 medications; and for a wider view across every procedure, see bariatric surgery overview.

Eligibility criteria (2026)

The 2022 ASMBS/IFSO joint guideline formally lowered the historic 1991 NIH thresholds. For adults, the current bariatric-surgery criteria are:

• BMI ≥ 40 — surgery is indicated with or without comorbidities.
• BMI ≥ 35 — surgery is indicated regardless of the presence of comorbidities under the 2022 update.
• BMI ≥ 30 with type 2 diabetes — a formal ASMBS 2022 lowered threshold; a growing but not yet universal insurance criterion.

For adolescents, the American Academy of Pediatrics 2023 guideline endorses referral for surgical evaluation at BMI ≥ 40, or ≥ 35 with a significant comorbidity, in patients who have reached Tanner stage 3 and near-final adult height. The Teen-LABS prospective cohort (Inge 2016 and 2019 5-year outcomes, NEJM) is the anchor evidence set: adolescent sleeve and bypass patients had 26% total-weight loss and 86% T2D remission at 5 years with a safety profile comparable to gallbladder surgery.

Insurance criteria lag the guideline slightly. Many commercial plans still require a documented 3–6 month supervised weight-loss attempt, a psychological evaluation, nutrition education visits, and treatment at an in-network MBSAQIP-accredited center. Coverage denials most often stem from missed documentation, not clinical ineligibility.

The procedure day by day

Two to four weeks before surgery — the liver-shrinking diet. Most programs prescribe a very-low-calorie (typically 800–1,000 kcal/day), protein-forward, low-carbohydrate diet — often meal-replacement shakes plus a small evening meal — to shrink the left lobe of the liver, which normally overhangs the stomach and blocks the surgeon’s view. Skipping this step meaningfully raises the intra-operative conversion rate.

Surgery day. Same-day admission, general anesthesia, laparoscopic or robotic approach with 4–6 small incisions. The surgeon divides the stomach along the greater curvature over a sizing bougie (typically 32–40 French) and removes the outer portion. The staple line is often reinforced or oversewn. Total operative time is usually 60–90 minutes; total time in the operating room including anesthesia induction and emergence is closer to two hours.

Postoperative day 0–1. Recovery in the PACU, transfer to a step-down floor, early ambulation within a few hours to reduce VTE risk, sips of clear liquids the evening of surgery. A gastrografin swallow study is sometimes done the morning of postop day 1 to rule out a leak.

First week home. Clear-liquid diet, incentive spirometry, walking multiple times daily, prophylactic anticoagulation in many programs, no lifting > 10 lbs. Pain is usually manageable on non-opioid regimens after the first 48 hours.

Weeks 1–2. Full-liquid diet (protein shakes, thin yogurt, broth). Return to desk-based work is typical. No driving until off narcotics.

Weeks 2–4. Pureed foods (blended protein, refried beans, cottage cheese). Portions are typically 2–4 ounces. Protein-first ordering starts.

Weeks 4–6. Soft foods (fish, ground meat, well-cooked vegetables). Structured exercise usually cleared at 6 weeks.

Month 2–6. Regular textures with strict portion limits. The bulk of weight loss happens in this window.

Long-term follow-up. Most programs schedule visits at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, then annually. Annual labs (CBC, iron studies, B12, 25(OH)D, PTH, calcium) continue for life.

Expected weight loss — what the trial data actually show

Four studies are the anchor evidence base most bariatric surgeons rely on when quoting expected results:

• SLEEVEPASS RCT (Salminen 2018 in JAMA Surgery; 10-year extension 2022 in JAMA Surgery). Randomized 240 patients to sleeve versus Roux-en-Y gastric bypass. At 10 years, mean %EWL was 47% for sleeve versus 55% for bypass — statistically different but with substantial overlap. Quality-of-life scores were similar.
• SM-BOSS RCT (Peterli 2018 in JAMA). Randomized 217 patients to sleeve versus bypass. At 5 years, %EWL was 61% for sleeve and 68% for bypass — the same directional pattern with a modest bypass advantage.
• STAMPEDE (Schauer 2017 in NEJM, 5-year outcomes). Adults with T2D and BMI 27–43 randomized to intensive medical therapy alone, medical + sleeve, or medical + bypass. Composite glycemic endpoint met by 5% (medical), 23% (sleeve), 29% (bypass) — the anchor evidence for surgical T2D remission.
• Swedish Obese Subjects (SOS) (Sjöström 2007 in NEJM; 20-year extension 2020). Prospective matched cohort of ~4,000 patients showing bariatric surgery reduced overall mortality by ~24% over two decades — the longest and largest bariatric outcome dataset in existence, dominated by older procedures but still cited for long-term mortality benefit.

The practical takeaway: a well-selected sleeve patient at an accredited center should expect 25–30% total-body weight loss at one year and roughly 20% still present at five years, with the caveat that adherence, follow-up engagement, and post-op behavior — protein, activity, tracking — modify those numbers by 5–10 percentage points in either direction.

Comorbidity improvement rates

Beyond weight, the sleeve produces meaningful improvement in most obesity-related conditions. Rates from the STAMPEDE 5-year data and SLEEVEPASS long-term follow-up:

• Type 2 diabetes: 40–60% remission at 1 year; sustained partial remission or improved glycemic control in most patients out to 5 years. Bypass runs slightly higher.
• Hypertension: 60–70% of patients on antihypertensives at baseline reduce or discontinue medications within a year.
• Obstructive sleep apnea: 60–80% experience clinically meaningful AHI reduction; many are able to discontinue CPAP after repeat sleep study.
• Non-alcoholic fatty liver disease (NAFLD): significant reduction in steatosis and fibrosis in longitudinal biopsy series.
• GERD: this is the key differentiator against bypass. Sleeve can worsen reflux in 20–30% of patients, and long-term follow-up shows a measurable Barrett’s esophagus rate at 10 years (SLEEVEPASS 2022). Bypass, by contrast, improves reflux. Pre-op reflux workup — often including endoscopy — is standard.

Risks and complications

Modern accredited-center sleeve gastrectomy is safe in absolute terms, but no operation is risk-free. Understanding the actual event rates is the difference between an informed decision and either overconfidence or fear.

• 30-day mortality: approximately 0.1% at MBSAQIP-accredited U.S. centers.
• Staple-line leak: ~1–2% — the most feared early complication; usually presents in the first 1–2 weeks with tachycardia, fever, or abdominal pain.
• Bleeding: ~1–2%; usually managed conservatively or endoscopically.
• Stricture: 1–4%, often at the incisura; treated with endoscopic dilation and sometimes conversion to bypass.
• New or worsened GERD: 20–30% at long-term follow-up; a meaningful rate of Barrett’s esophagus at 10 years.
• Venous thromboembolism (DVT/PE): < 1% with modern prophylaxis.
• Weight regain: 20–30% experience substantial regain by year 5–10; the stepwise response — GLP-1 rescue, endoscopic re-sleeve or TORe, and (rarely) surgical conversion — is in bariatric surgery revision.
• Nutritional deficiencies: B12, iron, vitamin D, calcium, thiamine, and folate are all measurable risks over time — lower than after bypass or duodenal switch, but real. Lifelong daily supplementation and annual labs are standard; the full stack is in the bariatric post-op vitamin and nutrition protocol.
• Gallstones: 10–30% develop new symptomatic gallstones in the first 6–12 months from the rapid post-op weight loss; many programs now prescribe prophylactic ursodeoxycholic acid (UDCA) for 6 months.
• Dumping syndrome: ~10–15% (lower than bypass, but real), usually responsive to low-glycemic, split-meal, fluids-between-meals patterns.

Cost and insurance

Cash-pay sleeve gastrectomy at an accredited U.S. center currently runs about $15,000–$25,000, depending on hospital, region, and included services. Bundled programs typically include surgeon, anesthesia, facility, and initial follow-up. Ongoing costs are meaningful too: bariatric multivitamins run $20–$50 per month, and annual lab panels plus periodic follow-up visits continue for life.

When commercial insurance or Medicare covers the procedure — which is the norm when the patient meets BMI and comorbidity criteria and completes the plan’s prior-authorization requirements — the patient typically pays deductible plus coinsurance ($2,000–$6,000 in-network is common) rather than the full sticker price. The path to coverage usually includes 3–6 months of supervised weight-loss attempts, a psychological evaluation, nutrition classes, and treatment at an in-network MBSAQIP center of excellence.

International medical tourism (Mexico, Turkey, Colombia) offers headline prices in the $4,500–$8,000 range for sleeve. The trade-offs are real and worth being explicit about: variable center accreditation, no follow-up integration with U.S. care teams, higher re-admission and complication rates in the first weeks back home, and no recourse if a leak or bleed appears after you have crossed a border. A full breakdown of what patients actually pay, insurance-approval timelines, and the medical-tourism risk math is in bariatric surgery cost and insurance coverage.

Alternatives if you don’t qualify or want to avoid surgery

• Endoscopic sleeve gastroplasty (ESG) — incisionless suturing through the mouth, no anatomy removed. Weight loss lands between the band and the sleeve (~15–20% TWL). Reversible. Appealing for lower-BMI patients or those who cannot accept anatomy removal.
• Gastric balloon procedures — a fluid- or gas-filled intragastric device left in place for 6 months. Modest weight loss (~10–15% TWL) as a bridge or a lower-BMI option.
• GLP-1 medications (semaglutide, tirzepatide) — 15–22% mean total-weight loss at full dose after 68–72 weeks. Reversible, no operative risk. See bariatric surgery vs GLP-1 medications for the direct comparison and when the two are combined.
• Prescription weight-loss medications beyond GLP-1s — phentermine, naltrexone-bupropion, others — for patients who don’t want or don’t qualify for GLP-1s.

How to choose a surgeon

Complication rates in bariatric surgery are strongly tied to surgeon and center volume. Choosing well is the single strongest lever a patient controls.

• MBSAQIP accreditation. The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program is the U.S. accreditation standard. Accredited centers meet defined volume, staffing, and outcomes-reporting requirements.
• Surgeon volume. Look for surgeons performing at least ~100 sleeves per year and centers doing several hundred bariatric cases annually. Published complication and leak rates for the surgeon should be available on request.
• Multidisciplinary team. Bariatric dietitian, psychologist or social worker, exercise specialist, and long-term follow-up infrastructure should be built in — not referred out.
• Long-term follow-up commitment. The program should describe a clear 2-week / 6-week / 3-month / 6-month / 12-month / annual schedule and the specific vitamin and lab protocol they follow.
• Honest pre-op reflux workup. If you have any history of GERD, a pre-op endoscopy and a candid conversation about sleeve versus bypass is a green flag.
• Red flags. Aggressive telesales, cash-only “specials,” no post-op follow-up plan, no dietitian on staff, unwillingness to share complication rates.

Sources at a glance

1. Salminen P et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years (SLEEVEPASS). JAMA Surgery, 2022.
2. Peterli R et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity (SM-BOSS). JAMA, 2018.
3. Schauer PR et al. Bariatric surgery versus intensive medical therapy for diabetes (STAMPEDE) — 5-year outcomes. NEJM, 2017.
4. Sjöström L et al. Effects of bariatric surgery on mortality in Swedish obese subjects (SOS). NEJM, 2007; 20-year extension 2020.
5. Inge TH et al. Weight loss and health status 3 and 5 years after bariatric surgery in adolescents (Teen-LABS). NEJM, 2016; 2019.
6. Eisenberg D, Shikora SA, Aarts E et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases, 2022.
7. Parrott J, Frank L, Rabena R et al. American Society for Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical weight loss patient — 2016 update: micronutrients. SOARD, 2017 (foundational; updated in 2022).